Eli Lilly to Pay $61 Million in Medicaid Pricing Fraud Suit
An Illinois jury said Eli Lilly and Co. must pay $61 million in a whistleblower’s fraud suit alleging that the company made false claims about pricing under Medicaid’s drug rebate program.
The trebled False Claims Act damages amount would exceed $183 million, plus penalties, according to a Wednesday press release by whistleblower Ronald J. Streck’s law firm, Walden Macht & Haran LLP.
“The jury has spoken. Eli Lilly knowingly violated the False Claims Act and defrauded the Medicaid Program of $61 million in taxpayer money,” said Dan Miller of Walden Macht & Haran LLP, lead counsel for Streck.
“We took on one of the biggest pharmaceutical companies in the world, and one of the largest law firms in the world, and we won,” he said.